XBP1 and plasma cell myeloma: For example, several compounds targeting either the ATP-binding pocket or the RNase domain of IRE1, and thereby reducing XBP1 mRNA cleavage, have been developed, and encouraging results in preclinical studies for multiple myeloma have been reported (60, 61).